Metrics raised 5
- FY27 capacity utilization target raised to 70-75% by year-end (from ~60% current; no prior guidance stated)
- FY27 volume growth target raised to 15-20% for full year (5-7% quarterly; no prior guidance stated)
- Isostearic acid utilization target raised to >80% in 1-2 years (no prior guidance stated; currently 4% of revenue)
- New 40,000 MTPA oleochemical plant and new R&D product trial runs in Q2 FY27 (no prior guidance stated; expected better margins)
- Export competitiveness targeted for structural improvement via India-UK FTA, expected India-EU FTA, US tariff benefits, and rupee depreciation (no numeric prior guidance)
Event Participants
Executives
2 Bhavesh Shah (Chief Financial Officer), Nahoosh Jariwala (Managing Director and Chairman)
Analysts
14 Ajay Surya (Niveshaay), Ashish Upganlawar (InvesQ PMS / InvestQ PMS), Chirag Vakaria (Budhrani Finance), Jasmine Surana (VT Capital), Madhur Rathi (Counter Cyclical Investment), Maitri Shah (Sapphire Capital), Pragyam Laddha (Omnee Management LLP), Preet Jain (Niveshaay), Rohit (I-Thought PMS), Rohan Joshi (Individual Investor), Sajal Kapoor (Antifragile Thinking), Shivam Gupta (Trinetra Asset Managers), Shivam Parekh (Valuewise Wealth Management), Shlok Patel (ZenFlow Research)
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue from Operations | ₹176 crores | +34.4% YoY driven by higher price realization from elevated raw material costs and reduced import pressure |
| EBITDA | ₹18 crores | Margin improved to 10.14% supported by better domestic realization as import pressure eases |
| Net Profit | ₹10 crores | No YoY comparison provided in transcript |
| Raw Material Processed | 12,400 tonnes | Operational throughput for the quarter |
| Volume Sold | 13,500 tonnes | +3.8% YoY vs 13,000 tonnes in Q1 FY26; growth primarily realization-driven |
| Capacity Utilization | ~60% | Targeting 70-75% by FY27 end on 80,000 MTPA current capacity |
| Export Revenue Share | 7-8% | Dimer acid and Isostearic acid key export products; targeting improvement via FTAs and rupee depreciation |
| Revenue Mix - Dimer Acid | 30% | Core product segment |
| Revenue Mix - Linoleic Acid | 42% | Largest segment; 40% of volume goes to paint industry as crude vegetable oil substitute |
| Revenue Mix - Isostearic Acid | 4% | Nascent segment; targeting >80% capacity utilization in 1-2 years |
| Revenue Mix - Other By-products | 24% | Balance of revenue |
| Realization Improvement (vs Q4 FY26) | +25% | Sequential improvement driven by supply chain constraints and reduced Chinese dumping |
| Realization Improvement (vs Q1 FY26) | +30% | Year-on-year improvement |
| Inverted Duty Impact | 9% margin loss | Raw material duty 16.5% vs finished product duty 7.5%; reduced from 27.5% in 2024 |
| R&D Expense (Revenue) | ~₹50 lakhs | 1-1.5% of sales including capital expenditure on need basis |
| Energy Conservation | Power -30%, Solid fuel -35% | Major exercise undertaken in FY26 reducing consumption significantly |
| New Customer Enquiries | 7-8 large customers | Supply chain diversification driving enquiries for alternative supply |
Geographic & Segment Commentary
Domestic Market (92-93% of revenue): Strong realization improvement of 25-30% driven by reduced Chinese import pressure and Middle East supply chain constraints. Paint industry accounts for 40% of revenue via linoleic acid as crude vegetable oil substitute. Management sees no intent to reduce paint industry dependence, instead targeting overall capacity utilization growth.
Export Market (7-8% of revenue): Dimer acid and Isostearic acid are key export products. India-UK FTA, expected India-EU FTA, favorable US tariff developments, and rupee depreciation expected to strengthen export competitiveness and support capacity utilization improvement.
Dimer Acid (30% of revenue): Core product facing historical Chinese dumping pressure. Current improvement attributed to reduced dumping (possibly due to reduced Chinese export incentives) and geopolitical supply constraints. Management cautions dumping could return.
Linoleic Acid (42% of revenue): Largest segment, directly substitutes crude vegetable oil derivatives in paint industry. Product upgradation using oil-sealed railings underway with customer trials ongoing; tailor-made product commands premium realization.
Isostearic Acid (4% of revenue): Third global manufacturer using green process route. Long gestation for cosmetic customer approvals (Europe/Japan) - currently at step 3-4 of 5-step qualification at multiple companies. Targeting >80% capacity utilization in 1-2 years; breakthrough with one major buyer could trigger volume surge.
By-products (24% of revenue): Includes bypass fat (few global manufacturers) and other oleochemical derivatives. New 40,000 MTPA oleochemical plant commissioning in Q2 FY27 with trial runs starting; expected to carry better margins than current portfolio.
Company-Specific & Strategic Commentary
Capacity Utilization Ramp-up: Targeting 5-7% quarterly volume growth (15-20% for full year) to move from 60% to 70-75% utilization on 80,000 MTPA capacity. New 40,000 MTPA capacity addition in Q2 will expand base for FY28. Management emphasizes volume growth over margin expansion at current levels.
Energy & Cost Structure Optimization: Completed major energy conservation exercise in FY26 reducing power consumption >30% and solid fuel >35%. Ongoing catalyst and consumable optimization to reduce consumption and cost. Continuous time-and-motion studies to prevent excess manpower.
R&D and Product Innovation: In-house R&D developed new oleochemical product launching Q2 (first-time manufacturing globally for Fairchem). Isostearic acid green process is key differentiator - only 3rd global manufacturer. R&D spend at 1-1.5% of sales; management acknowledges reporting transparency improvement needed. Innovation cycle long (pilot → small plant → commercial) with no off-the-shelf technologies.
Supply Chain Diversification Tailwind: 7-8 large global customers actively enquiring for alternative supply sources amid China+1 strategies. Management sees meaningful increase in enquiries but avoids long-term contracts due to volatility preference.
Conservative Financial Posture: Zero debt, no aggressive expansion even during favorable cycles. Inverted duty structure (9% margin leakage) acknowledged but company too small to influence policy. Chinese dumping sustainability uncertain - viewed as business risk requiring cautious approach.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Capacity Utilization (FY27) | 70-75% by year-end | From current ~60% on 80,000 MTPA; driven by 5-7% quarterly volume growth |
| Volume Growth (FY27) | 15-20% for full year | 5-7% per quarter; first step to 100% utilization before further capacity addition |
| Revenue & Margin Run Rate | Maintain current levels | Management confident of sustaining Q1 realization and margin trajectory |
| Isostearic Acid Utilization | >80% in 1-2 years | Dependent on cosmetic customer qualification completion; breakthrough potential |
| New Product Launch | Q2 FY27 trial runs | 40,000 MTPA oleochemical plant; in-house R&D developed; better margins than current |
| Export Competitiveness | Structural improvement | India-UK FTA, expected India-EU FTA, US tariff benefits, rupee depreciation to support exports |
| Chinese Dumping Risk | Uncertain sustainability | Reduced dumping currently (possibly lower Chinese export incentives); could return |
Risks & Constraints
| Risk | Context |
|---|---|
| Chinese Dumping Resumption | Dumping reduced currently (import quantities down, prices up) but could restart if Chinese export incentives return or geopolitical situation eases. Management views this as key business risk limiting aggressive expansion. |
| Inverted Duty Structure | 9% margin leakage (16.5% raw material duty vs 7.5% finished product duty) persists since 2024 (reduced from 27.5%). Company too small to effectively lobby for correction; structural disadvantage vs integrated global peers. |
| Geopolitical Volatility | Middle East crisis creating supply chain constraints currently benefiting realization. Resolution could reverse price gains. Rupee depreciation helps exports but increases imported input costs (though company claims 100% domestic raw material sourcing). |
| Isostearic Acid Commercialization Delay | Long gestation for cosmetic approvals (Europe/Japan) - currently at steps 3-4 of 5. Only 3 global manufacturers creates high entry barriers. Revenue contribution remains minimal (4%) until major buyer qualification completes. |
| Customer Concentration & Contract Risk | Management refuses long-term contracts due to volatility ("hara-kiri"). No volume commitments without price commitments from customers. Limits revenue visibility despite 7-8 new large customer enquiries. |
| Raw Material Price Volatility | Linoleic acid (42% revenue) substitutes crude vegetable oil; price correlation creates pass-through risk. Realization gains currently from supply constraints, not structural pricing power. |
Q&A Highlights
Guidance & Capacity Utilization
Question: What is current capacity utilization and FY27 guidance? (Rohan Joshi)
Answer: Currently ~60%, targeting 70-75% by FY27 end on 80,000 MTPA capacity. New 40,000 MTPA adds in Q2 for FY28 base. (Bhavesh Shah, Nahoosh Jariwala)
Question: Is 30% volume growth sustainable and what drives it? (Madhur Rathi)
Answer: Q1 volume growth only ~3.8% YoY (13,500 vs 13,000 tonnes); 34.4% revenue growth was realization-driven. Targeting 5-7% quarterly volume growth (15-20% full year) via utilization improvement. (Bhavesh Shah, Nahoosh Jariwala)
Margin Sustainability & Chinese Dumping
Question: Can you segregate margin impact from inverted duty vs dumping? (Ashish Upganlawar)
Answer: Inverted duty causes 9% margin loss (16.5% vs 7.5% differential). Dumping reduction is separate - Chinese imports down, prices up. Sustainability uncertain as Chinese policy changes unpredictable. (Bhavesh Shah, Nahoosh Jariwala)
Question: If supply constraints ease but Chinese dumping stays low, what revenue growth? (Maitri Shah)
Answer: Primary target is capacity utilization increase (10-20% for year). Geopolitical situation plays big part. No specific revenue guidance given. (Nahoosh Jariwala)
Isostearic Acid Ramp-up
Question: What is realistic ramp-up for Isostearic acid given long approval cycles? (Madhur Rathi, Rohit)
Answer: At step 3-4 of 5 with multiple cosmetic companies (Europe/Japan). Green process USP but requires extensive stability testing. Expect positive outcome by FY27 end. >80% utilization target in 1-2 years. Breakthrough with one major buyer could surge volumes. (Nahoosh Jariwala)
Question: Is Isostearic acid material to current results? (Ashish Upganlawar)
Answer: Only 4% of Q1 revenue. Current results purely from dimer/linoleic/other acids improvement. Isostearic is forward integration adding value to by-product stream, not core utilization driver. (Bhavesh Shah, Nahoosh Jariwala)
New Product & Capacity Expansion
- Question: Details on new 40,000 MTPA product launching Q2? (Preet Jain, Madhur Rathi)
- Answer: Oleochemical family product, first-time manufacturing globally for Fairchem, in-house R&D developed. Trial runs starting Q2, then ramp-up. Margins better than current portfolio. Specific product not disclosed. (Nahoosh Jariwala, Bhavesh Shah)
Export Strategy & Customer Diversification
Question: Export contribution and key products? (Rohan Joshi)
Answer: 7-8% of revenue currently. Dimer acid and Isostearic acid key export products. FTAs and rupee depreciation expected to improve competitiveness. (Nahoosh Jariwala, Bhavesh Shah)
Question: Are customers willing to sign long-term contracts? (Ajay Surya)
Answer: No long-term contracts due to volatility. Customers won't commit volume without price commitment. Management prefers flexibility. (Nahoosh Jariwala)
R&D & Innovation
- Question: R&D spend and innovation pipeline? (Sajal Kapoor)
- Answer: ~₹50 lakhs revenue expense (1-1.5% of sales including capex). 13 technical resources including 1 PhD. New product launching Q2. Innovation cycle long (pilot→small→commercial), all self-developed. Competitive advantage is manufacturing know-how, not patents. (Nahoosh Jariwala, Bhavesh Shah)
Competitive Positioning
- Question: Structural cost advantages beyond